Status:
UNKNOWN
Acetazolamide for Treating NPH in Shunt-candidates Patients
Lead Sponsor:
Rabin Medical Center
Conditions:
Normal Pressure Hydrocephalus
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
Normal pressure hydrocephalus (NPH) consists of a triad of gait disturbance, cognitive deterioration, and urinary incontinence and is characterized by enlarged cerebral ventricles. Current treatment r...
Eligibility Criteria
Inclusion
- Included will be subjects with a probable diagnosis of NPH. The diagnosis will be based primarily on presence of gait impairment plus at least one other impairment in urinary symptoms, cognition impairment or both.
- Are 50 years old or older.
- Patients who meet the criteria for NPH based on:
- A typical personal history.
- A typical brain imaging on head CT or MRI.
- Normal lumbar puncture findings excluding other conditions.
- Exclusion of other more likely diagnosis.
- Patients who underwent large-volume spinal tap and subsequently improved clinically by at least 10% in gait function or cognition.
Exclusion
- Cirrhosis or marked liver disease or dysfunction.
- Severe renal disease or dysfunction.
- Acidosis.
- Hypersensitivity to acetazolamide, sulfonamides, or any component of the formulation.
- Decreased sodium and/or potassium levels.
- Adrenocortical insufficiency.
- Patients with cognitive impairment who will not be able to give informed consent.
Key Trial Info
Start Date :
December 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2019
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT03779594
Start Date
December 1 2018
End Date
December 1 2019
Last Update
December 19 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rabin Medical Center
Petah Tikva, Israel, 49100